Follow last change Jun 2019 re-read 3 minutes ago

VIF

also known as pVIF

Developed for: coronary artery disorder
Investigated by: Center of Oncology, Warsaw, Poland · Medical University of Warsaw · Ministry of Scientific Research and Information Technology, Poland · National Institute of Cardiology, Warsaw, Poland · Polpharma Foundation for Development of Polish Pharmacy and Medicine

today NCT00620217 · Ph 2

20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT00620217	Dec 2004 → May 2008	coronary artery disorder	National Institute of Cardiology, Warsaw, Poland	Completed	Missed primary

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	VIF	“VIF group received electromechanical system NOGA-guided intramyocardial injections of VEGF-A165/bFGF plasmid (VIF) into ischemic regions, while the Placebo group-placebo...” PMID 31288177 ↗ Jun 2019
Known as	pVIF	“BACKGROUND: VIF-CAD randomized, placebo-controlled, double-blind trial was an attempt to induce therapeutic angiogenesis by percutaneous intramyocardial transfer of bicistronic...” PMID 21392615 ↗ Jan 2011
Modality	Other / unclassified	“Achieving therapeutic angiogenesis with gene therapy using a plasmid coding human VEGF-A165/bFGF” NCT00620217 ↗
Route	Other	“intramyocardial injections of VEGF-A165/bFGF plasmid” PMID 31288177 ↗ Jun 2019